PURPOSE: To evaluate in a retrospective study the long-term usefulness of red 647 nm krypton and 670 nm diode laser for transscleral contact cyclophotocoagulation (CPC) in the treatment of therapy-resistant inflammatory @entity726 . METHODS: The authors treated 48 eyes of 38 consecutive @entity1 (mean age 36.8 years, range 6-81 years) with therapy-resistant inflammatory @entity726 secondary to chronic @entity1596 (45/48), @entity3170 (1/48), or @entity3170 with keratouveitis (2/48) using transscleral red 647 nm Krypton or 670 nm Diode laser. All eyes had failed maximum tolerated medical therapy and 19/48 (40%) eyes also previous antiglaucoma surgery. Laser power at the scleral surface was 0.35 to 0.45 W and the application time 10 seconds each. The follow-up was 42.8 40.0 (range 2-145) months. RESULTS: The mean preoperative intraocular pressure (IOP) of 35.68.1 mmHg fell to 6-21 mmHg level in 75% after one or repeated CPC. Among adult @entity1 this was achieved in 85%, among @entity1 in 54%. More than one treatment was needed in 52%. No cases of @entity8814 , phthisis bulbi, or other devastating complications occurred. CONCLUSIONS: Transscleral CPC using red 647 nm krypton or 670 nm diode laser is an effective and well-tolerated procedure for the treatment of therapy-resistant inflammatory @entity726 in adults. CPC can be considered before incisional antiglaucoma surgery with a shunt or antimetabolites is undertaken.

Transscleral red laser cyclophotocoagulation for the treatment of therapy-resistant inflammatory XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity1596 :: ('MESH:D014605', 'Disease') :: ['uveitis'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity8814 :: ('MESH:D015814', 'Disease') :: ['hypotony'] @entity3170 :: ('MESH:D015423', 'Disease') :: ['chronic scleritis', 'combined scleritis']
@entity726 :: (MESH:D005901,Disease) :: ['glaucoma']
